Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay

Figure 2

Median inhibition by zoledronic acid and fluvastatin alone and in combination in a) breast carcinomas tested with fluvastatin concentration A (n = 9); b) ovarian carcinomas tested with fluvastatin concentration A (n = 8) and c) ovarian carcinomas tested with fluvastatin concentration B (n = 14). The combination results are expressed as micromolar concentrations of zoledronic acid.

Back to article page